Bortezomib for the treatment of multiple myeloma-Reference-Cited by-同舟云学术

Bortezomib for the treatment of multiple myeloma

Published:2016-04-20 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Scott Kathleen¹²,Hayden Patrick J³,Will Andrea⁴,Wheatley Keith⁵,Coyne Imelda¹

Affiliation:

1. Trinity College Dublin; School of Nursing & Midwifery; 24 D'Olier St Dublin Ireland

2. All Ireland Cooperative Oncology Research Group (ICORG); 60 Fitzwilliam Square Dublin Ireland

3. St James´s Hospital; Dublin Ireland

4. University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50937

5. University of Birmingham; Cancer Research Clinical Trials Unit, School of Cancer Sciences; Edgbaston Birmingham UK B15 2TT

Publisher

Wiley

Subject

Pharmacology (medical)

Reference81 articles.

1. Sahai S Kumar L Raina V Sharma A Gupta R Mahajan S Multiple myeloma with light chain-induced acute renal failure - role of bortezomib-dexamethasone & cyclophosphamide-thalidomide & dexamethasone: a prospective randomized study (Abstract 3648) Proceedings of the European Cancer Congress Amsterdam

2. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study;Chanan-Khan;Journal of Clinical Oncology,2008

3. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study;Lee;British Journal of Haematology,2008

4. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma;Richardson;New England Journal of Medicine,2005

5. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial;Richardson;Blood,2007

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Ubiquitination and Proteostasis in Retinal Degeneration;Frontiers in Bioscience-Landmark;2024-07-22

2. Targeting apoptotic pathways for cancer therapy;Journal of Clinical Investigation;2024-07-15

3. Multiple myeloma: signaling pathways and targeted therapy;Molecular Biomedicine;2024-07-04

4. Development of Epigenetic Modifiers with Therapeutic Potential in FMS-Related Tyrosine Kinase 3/Internal Tandem Duplication (FLT3/ITD) Acute Myeloid Leukemia and Other Blood Malignancies;ACS Pharmacology & Translational Science;2024-07-02

5. Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma;American Journal of Hematology;2024-06-10